Desmethyl Erlotinib NEW
Price | $48 | $70 | $117 |
Package | 1mg | 2mg | 5mg |
Min. Order: | |
Supply Ability: | 10g |
Update Time: | 2024-11-09 |
Product Details
Product Name: Desmethyl Erlotinib | CAS No.: 183321-86-0 |
Purity: 98.62% | Supply Ability: 10g |
Release date: 2024/11/09 |
Product Introduction
Bioactivity
名稱 | Desmethyl Erlotinib |
描述 | Desmethyl Erlotinib (CP-473420) is the active metabolite of Erlotinib (EGFR inhibitor with IC50 of 2 nM). |
存儲(chǔ)條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | Ethanol : < 1 mg/mL (insoluble or slightly soluble) H2O : < 1 mg/mL (insoluble or slightly soluble) DMSO : 83 mg/mL (199.58 mM), Heating is recommended. |
關(guān)鍵字 | Drug Metabolite | Inhibitor | CP 373420 | CP-373420 | CP373420 | inhibit | CP473420 | OSI420 | Desmethyl Erlotinib | CP 473420 | OSI 420 |
相關(guān)產(chǎn)品 | Mycophenolate Mofetil | Osimertinib | CLOZAPINE N-OXIDE | Lidocaine Hydrochloride hydrate | Lapatinib | Erlotinib hydrochloride | Erlotinib | Neratinib | Isonicotinic acid | Ampyrone | Genistein | Gefitinib |
相關(guān)庫 | 細(xì)胞重編程化合物庫 | 抗胰腺癌化合物庫 | 經(jīng)典已知活性庫 | 膜蛋白靶向化合物庫 | 酪氨酸激酶分子庫 | 激酶抑制劑庫 | 血管生成庫 | 抑制劑庫 | 抗前列腺癌化合物庫 | 已知活性化合物庫 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY